Prosztatarák: nyitott vizsgálatok itt: Thaiföld
6 trials · From ClinicalTrials.gov, checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Bangkok, Bangkoknoi, Hat Yai, Muang
- Age
- 18 év and over
- People
- 1310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624EU 2023-504899-25-00Regiszter frissítve: 2026-11-05
3. fázisToborozTrial-stage medicine
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Where
- Bangkoknoi, Dusit
- Age
- 18 év and over
- People
- 1440 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06925737EU 2024-517423-40-00Regiszter frissítve: 2026-10-30
3. fázisToborozTrial-stage medicine
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Where
- Bangkoknoi, Hat Yai, Muang, Pathumwan
- Age
- 18 év and over
- People
- 1314 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136650EU 2023-504957-11-00Regiszter frissítve: 2026-10-20
3. fázisToborozTrial-stage medicine
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Bangkok
- Age
- 18 év and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110Regiszter frissítve: 2026-10-19
3. fázisToborozTrial-stage medicine
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Where
- Bangkok, Khlong Luang, Songkhla
- Age
- 18 év and over
- People
- 1330 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07711002EU 2026-526275-38-00Regiszter frissítve: 2026-10-15
3. fázisToborozTrial-stage medicine
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Where
- Bangkok, Khon Kaen, Muang, Pathum Thani, Songkhla
- Age
- 18 év and over
- People
- 700 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06952803EU 2024-513586-39-00Regiszter frissítve: 2026-10-14
Minden vizsgálat (Prosztatarák) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.